Pomaglumetad methionil

DRUG3 trials

Sponsors

Eli Lilly and Company, University of California, Los Angeles, New York State Psychiatric Institute

Conditions

Clinical High Risk for PsychosisMethamphetamine Use DisorderSchizophrenia

Phase 1

Study of Pomaglumetad and Methamphetamine

TerminatedNCT03106571

University of California, Los AngelesMethamphetamine Use Disorder

Start: 2017-08-01End: 2020-07-31Updated: 2020-09-01

Glutamate Reducing Interventions in Schizophrenia

CompletedNCT03321617

New York State Psychiatric InstituteClinical High Risk for Psychosis

Start: 2018-04-17End: 2020-03-13Updated: 2021-12-01

Phase 3

A Long-Term Study in Schizophrenia

TerminatedNCT01487083

Eli Lilly and CompanySchizophrenia

Start: 2011-12-31End: 2012-10-31Target: 282Updated: 2013-01-21